Canada is now the third market globally to receive approval of Descovy for the PrEP indication following the approval by the US Food and Drug Administration in October, 2019, and the Taiwan Food and Drug Administration in August, 2020.
Descovy is indicated for PrEP to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing ≥ 35 kg, excluding individuals at risk from receptive vaginal sex.
Descovy is taken orally once daily with or without food. Descovy is also approved in Canada for the treatment of HIV-1 infection in adults and pediatric patients weighing ≥ 25 kg, in combination with other antiretroviral agents.
PrEP is an HIV prevention strategy to reduce the risk of acquiring HIV infection. It can be taken by HIV-negative individuals considered at high risk of infection.
PrEP is taken daily, on an ongoing basis, in advance of high-risk activity.
According to the Public Health Agency of Canada, when medication for PrEP is taken as prescribed, the medication reduces the risk of acquiring sexually transmitted HIV by more than 90 per cent.
Before prescribing Descovy for PrEP, healthcare providers must counsel all uninfected individuals to strictly adhere to the recommended Descovy dosing schedule and must screen all individuals for HIV-1 immediately prior to initiating Descovy for PrEP and at least once every three months while taking Descovy, and upon diagnosis of any other sexually transmitted infections.
The PrEP indication is based on data from the Descovy trial, a multi-year global Phase 3 registrational clinical trial that evaluated the safety and efficacy of Descovy for PrEP compared with that of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF) for PrEP in reducing the risk of acquiring HIV-1 infection.
Enrollment included more than 5,300 adult cisgender men who have sex with men or transgender women who have sex with men.
Gilead Sciences is a US-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.
Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead Sciences Canada, Inc. is the Canadian affiliate of Gilead Sciences, Inc. and was established in Mississauga, Ontario, in 2006.
Gentian Diagnostics' SARS-CoV-2 test moves to optimisation phase
ViiV Healthcare wins FDA approval for HIV treatment Cabenuva
Incyte granted FDA priority review for retifanlimab BLA for SCAC
Cerba Research reports launch of time-saving COVID-19 exploratory tools and NGS advancements
Brigham Young University announces alcohol free Disinfect & Shield kills COVID-19 on contact
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases
FDA Grants Priority Review to Genentech's Esbriet for Unclassifiable Interstitial Lung Disease
Turn Therapeutics Authorized to Start Human Trial for COVID-19 Therapeutic Candidate
First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda
VBI Vaccines Updates Progress of Coronavirus Vaccine Program
EuBiologics Receives IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea
Enhertu Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer